Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers

Inclusion Criteria: * Medically healthy with no clinically significant findings in the screening results * Non-tobacco/nicotine-containing product users * Acceptably high normal (\>3 log10) flora counts from the designated skin sites on Day -4. * Voluntarily consent to participate in the study. * Females reporting spontaneous postmenopausal status * WOCBP must either be sexually inactive (abstinent) for 14 days prior to screening and remain so through 30 days following administration (topical dosing) of the study drug or have been using acceptable methods of birth control for the times specified * WOCBP who have undergone sterilization procedures 6 months prior to Day 1 Exclusion Criteria: * History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic (including sensitive skin on the face), neurological, or psychiatric disease, or any other clinically significant disease not deemed acceptable by the PI. * Evidence of compromise to skin integrity of forehead or cheek caused by acute rash, exacerbation of dermatitis, exacerbation of acne, or any other acute condition deemed clinically significant by the PI. * Tattoo, scar, keloid, or other chronic skin condition located on forehead or cheek * Facial hair growth that would interfere with sample collection procedures. * Positive urine drug/alcohol or cotinine testing * Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV). * History or presence of alcoholism or drug abuse within the 2 years prior to Day 1. * Hypersensitivity or idiosyncratic reaction to any ingredients in ALT005. * Use of any prescription medication started within 90 days prior to Day 1 * Use of any over-the-counter (OTC) medication, including herbal products, within the 14 days prior to the Day 1 * Blood donation or significant blood loss within 56 days prior to Day 1 * Plasma donation within 7 days prior to Day 1 * Participation in another clinical trial within 30 days prior to Day 1 * Females who are pregnant or lactating, or have a positive pregnancy test at screening or check-in * Failure to comply with the pre-treatment restrictions related to showering/washing and contact with antimicrobial substances.